[go: up one dir, main page]

AU2001233726A1 - Farnesyl protein transferase inhibitors for treating breast cancer - Google Patents

Farnesyl protein transferase inhibitors for treating breast cancer

Info

Publication number
AU2001233726A1
AU2001233726A1 AU2001233726A AU3372601A AU2001233726A1 AU 2001233726 A1 AU2001233726 A1 AU 2001233726A1 AU 2001233726 A AU2001233726 A AU 2001233726A AU 3372601 A AU3372601 A AU 3372601A AU 2001233726 A1 AU2001233726 A1 AU 2001233726A1
Authority
AU
Australia
Prior art keywords
breast cancer
protein transferase
transferase inhibitors
farnesyl protein
treating breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233726A
Other languages
English (en)
Inventor
Ivan David Horak
Peter Albert Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001233726A1 publication Critical patent/AU2001233726A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001233726A 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitors for treating breast cancer Abandoned AU2001233726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200373 2000-02-04
EP00200373 2000-02-04
PCT/EP2001/001032 WO2001056552A2 (en) 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitors for treating breast cancer

Publications (1)

Publication Number Publication Date
AU2001233726A1 true AU2001233726A1 (en) 2001-08-14

Family

ID=8170976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233726A Abandoned AU2001233726A1 (en) 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitors for treating breast cancer

Country Status (13)

Country Link
US (4) US20030027839A1 (de)
EP (1) EP1255537B1 (de)
JP (1) JP5491681B2 (de)
AT (1) ATE323474T1 (de)
AU (1) AU2001233726A1 (de)
CA (1) CA2396865C (de)
CY (1) CY1105477T1 (de)
DE (1) DE60118889T2 (de)
DK (1) DK1255537T3 (de)
ES (1) ES2262626T3 (de)
PT (1) PT1255537E (de)
SI (1) SI1255537T1 (de)
WO (1) WO2001056552A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
US20030185831A1 (en) * 2001-11-30 2003-10-02 Schering Corporation Methods of treating cancer using an FPT inhibitor and antineoplastic
US7102251B2 (en) * 2003-08-22 2006-09-05 Distributed Power, Inc. Bi-directional multi-port inverter with high frequency link transformer
MXPA06005031A (es) * 2003-11-06 2006-07-06 Schering Corp Combinacion de un inhibidor de la farnesil transferasa con un agente antihormonal para el tratamiento de cancer mamario.
TW200529845A (en) 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2288195B1 (de) * 2009-08-20 2019-10-23 Samsung Electronics Co., Ltd. Verfahren und Vorrichtung zum Betreiben einer Basisstation in einem drahtlosen Kommunikationssystem
CA2888480C (en) 2012-10-16 2021-03-16 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of ror.gamma.t
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
PE20151203A1 (es) 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
SG10202101740QA (en) 2015-08-17 2021-04-29 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
SMT202100207T1 (it) 2016-11-03 2021-07-12 Kura Oncology Inc Inibitori della farnesiltransferasi per il trattamento del cancro

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215541T1 (de) * 1995-12-08 2002-04-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
HUP0001122A3 (en) * 1997-04-25 2002-03-28 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU760028B2 (en) * 1998-07-02 2003-05-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9911861A (pt) * 1998-07-06 2001-03-20 Janssen Pharmaceutica Nv Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
AU4925199A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
TR200101961T2 (tr) * 1998-12-23 2001-12-21 Janssen Pharmaceutica N.V. 1,2-halkalı kinolin türevleri
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
EP1267848B1 (de) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20020022633A1 (en) * 2000-06-30 2002-02-21 Williams Theresa M. Inhibitors of prenyl-protein transferase

Also Published As

Publication number Publication date
DE60118889T2 (de) 2006-11-30
ATE323474T1 (de) 2006-05-15
EP1255537A2 (de) 2002-11-13
US20040192726A1 (en) 2004-09-30
US20090018164A1 (en) 2009-01-15
SI1255537T1 (sl) 2006-10-31
CA2396865C (en) 2009-04-14
US20030027839A1 (en) 2003-02-06
DK1255537T3 (da) 2006-08-21
PT1255537E (pt) 2006-09-29
JP5491681B2 (ja) 2014-05-14
WO2001056552A3 (en) 2002-04-25
JP2003521509A (ja) 2003-07-15
ES2262626T3 (es) 2006-12-01
WO2001056552A2 (en) 2001-08-09
EP1255537B1 (de) 2006-04-19
US20110098318A1 (en) 2011-04-28
CA2396865A1 (en) 2001-08-09
DE60118889D1 (de) 2006-05-24
CY1105477T1 (el) 2010-04-28

Similar Documents

Publication Publication Date Title
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
PL367682A1 (en) Dolastatin 10 derivatives
MY148632A (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
NO965604L (no) Histidin- og homohistidin-derivater som inhibitorer for protein-farnesyltransferase
MY117961A (en) Inhibitors of farnesyl protein transferase
GB0112348D0 (en) Compounds
AU5783300A (en) Anilinoquinazolines as protein tyrosine kinase inhibitors
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
MXPA04001646A (es) Composicion oftalmica que comprende ascomicina.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
MXPA04008303A (es) Inhibidores de la farnesil proteina transferasa como agentes antitumorales.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA03005374A (es) Carbazoles antitumorales.
NZ336042A (en) Farnesyl transferase inhibitors
AU2003236701A1 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
HK1054226A1 (zh) 0ovel法呢基蛋白轉移酶抑制劑
AU2001238499A1 (en) Nitroacridine/tumor inhibitor compositions
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
AU2002359762A1 (en) Luminacin analogs and uses thereof
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.